Dyax Corp

Dyax — Investor Presentation (January 2015)

21 slides from Dyax's investor presentation, Jan 12, 2015

  1. Slide 1: January 2015 Corporate Presentation

    1: January 2015 Corporate Presentation SubTitle: January 12, 2015

  2. Slide 2: Forward Looking Statements

    2: Forward Looking Statements Other Placeholder: 2 This presentation contains forward-looking statements regarding Dyax’s business plans, strategies and outlook. These statements may include, without limitation: statements regarding the potential benefits and usage of KALBITOR® (ecallantide) for tre

  3. Slide 3: Dyax: An Evolving Orphan Disease Company

    3: Dyax: An Evolving Orphan Disease Company Other Placeholder: 3 Platform company HAE company Kinin pathway company Orphan disease company Phage display technology(Licensing & Funded Research Portfolio) DX-2930, preclinical candidates Future pipeline candidates

  4. Slide 4: Multiple Value Drivers

    4: Multiple Value Drivers Other Placeholder: 4 KALBITOR® (ecallantide)DX-2930Future Pipeline Candidates Approved ProductClinical Stage Product CandidatesRoyalties/Milestones PRODUCT & DEVELOPMENT PORTFOLIO LICENSING PORTFOLIO

  5. Slide 5: Dyax Product Strategy

    Dyax Product Strategy High unmet need Access multiple indications Validated target Low risk therapeutic molecule

  6. Slide 6: Product and Development Portfolio

    6: Product and Development Portfolio Other Placeholder: Current focus on plasma kallikrein-kinin systemKALBITOR® (ecallantide) FDA approved product for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and olderPeptide inhibitor of plasma kallikreinDX-2930Clin

  7. Slide 7: HAE Disease Profile

    7: HAE Disease Profile Other Placeholder: 7 Rare, genetic disease characterized by unpredictable episodes of severe, painful swelling1Attacks can affect abdomen, face, larynx and/or extremities1 Patients suffer variable number of attacks per yearThreat of mortality from laryngeal edema2Level of depr

  8. Slide 8: KALBITOR (ecallantide)

    8: KALBITOR®(ecallantide) Other Placeholder: 8 Available in the U.S. to treat acute HAE attacks in patients age 12+Approved for treating all attack locations including hands, feet, face, abdomen, genitals and throatIn clinical trials, KALBITOR improved attack symptoms at 4 hours and demonstrated sus

  9. Slide 9: KALBITOR Business

    9: KALBITOR Business Other Placeholder: KALBITOR business is profitable and cash flow positive3Q14 net sales were $20.3 million (nine months YTD = $49.4 million)Recent revenue growth driven by:Treatment rateNew patientsPatient focused market strategy: identifying and helping the right HAE patients r

  10. Slide 10: DX-2930 – Built by Dyax

    10: DX-2930 – Built by Dyax Fully human monoclonal antibody for the potential prophylactic treatment of HAETargets same pathway as KALBITORHigh affinity for activated plasma kallikrein (Ki = 125 pM)Does not target prekallikreinDoes not inhibit any other tested serine proteaseHigh concentration formu

  11. Slide 11: DX-2930 Phase 1b Study in HAE Patients

    11: DX-2930 Phase 1b Study in HAE Patients Other Placeholder: Ascending repeat dose study of subcutaneous DX-2930 in HAE patients to assess safety, pharmacokinetics and pharmacodynamicsRandomized, double-blind, placebo-controlledEnrollment of 36 patients5 dose groups: 30 mg, 100 mg, 300 mg, 400 mg,

  12. Slide 12: Summary of DX-2930 Phase 1a Study

    12: Summary of DX-2930 Phase 1a Study Other Placeholder: Pharmacokinetic (PK) profile suggests feasibility of attaining stable target blood levelDose proportional exposure Long half-life (approximately 17-21 days) following single dose in healthy subjectsPharmacodynamic (PD) data consistent with obs

  13. Slide 13: Key Attributes of a Prophylactic Agent

    13 Clinically relevant target Plasma kallikrein is central to kinin pathway activationDX-2930 has high affinity for plasma kallikrein (Ki=125 pM) Safe for chronic use Avoidance of off-target effects - no inhibition of any serine protease testedPrekallikrein deficiency is asymptomatic Long half-life

  14. Slide 14: PKM Disorders Beyond HAE

    14: PKM Disorders Beyond HAE Other Placeholder: Determine if plasma kallikrein activation occurs as part of other inflammatory disorders:Diabetic macular edemaUlcerative colitis Crohn’s diseaseRheumatoid arthritisUsing a number of tools to explore the plasma kallikrein pathway:Biomarker assaysLitera

  15. Slide 15: Licensing Portfolio

    15: Licensing Portfolio Other Placeholder: 15

  16. Slide 16: Dyax Licensing Portfolio

    16: Dyax Licensing Portfolio Other Placeholder: Built around proprietary antibody discovery technologyAddressing significant therapeutic marketsLicensing agreements with top-tier companiesMultiple late-stage clinical programs Several product development events projected in the next 12 months All ant

  17. Slide 17: Licensee compound and indication programs by phase

    17 Lilly Lilly CYRAMZA® (ramucirumab ) (VEGFR-2/KDR)Gastric cancer (REGARD)Gastric cancer (RAINBOW)NSCLC (REVEL)Hepatocellular cancer (REACH)Colorectal cancer (RAISE)Necitumumab (IMC-11F8) (EGFR)NSCLC (SQUIRE)Trebananib+ (AMG 386) (Ang-1/Ang-2)Ovarian cancer (TRINOVA-2 and -3)Ramucirumab – multiple

  18. Slide 18: Financials and Key Drivers

    18 Title: Financials and Key Drivers

  19. Slide 19: Financial Highlights

    19: Financial Highlights Financial guidance for 2015 will be presented in conjunction with the release of 4Q and year-end 2014 financial results. Other Placeholder: 19 Source: Dyax 3Q14 press release issued on October 28, 2014

  20. Slide 20: Near-Term Catalysts

    20: Near-Term Catalysts *Based on information publicly disclosed by licensees; current as of Jan. 8, 2015

  21. Slide 21: IR Contact

    21: IR Contact:Mary jenkinsmjenkins@dyax.com617-250-5543 January 2015 Corporate Presentation

Dyax — Investor Presentation (January 2015) on 6ix